Conference Coverage
Conference Coverage
VIDEO: Longer HCV therapy worked even after short-term failures
Patients with HCV who fail short-course antiviral treatment may still be able to achieve a cure using longer-duration therapies plus ribavirin.
Conference Coverage
Multitargeted drug combination promising when new HCV antivirals fail
Key clinical point: A five-drug antiviral combination appears to be effective for retreatment of patients with hepatitis C virus infection who...
Conference Coverage
Regimen effective in genotype 3 HCV despite advanced cirrhosis
Sustained virologic response in patients with genotype 3 hepatitis C virus (HCV) infection and advanced fibrosis or cirrhosis was achieved in 88%...
Conference Coverage
VIDEO: Antigen test could simplify HCV screening
A new test focused on hepatitis C antigen detection might simplify the HCV screening process and reduce its costs.
Conference Coverage
VIDEO: Inappropriate hepatitis A, B tests may be widespread in hospitals
Hospital physicians may be ordering too many inappropriate lab tests in cases of suspected acute hepatitis A and hepatitis B.
Conference Coverage
Novel botanical drug reduces hepatic fat content
Twelve weeks of treatment with a novel botanical drug extracted from Magnolia officinalis safely and significantly reduced hepatic fat content in...
Conference Coverage
Cysteamine bitartrate provides no histologic improvement in children with NAFLD
One year of treatment with delayed-release cysteamine bitartrate was safe and associated with substantial and rapid improvements in liver enzymes...
Conference Coverage
ASTRAL-1: High SVR12 with sofosbuvir/velpatasvir combo for HCV
Once-daily treatment with fixed-dose combination sofosbuvir/velpatasvir for 12 weeks was well tolerated and resulted in high sustained virologic...
Conference Coverage
Cellular therapy benefit limited to young alcoholic hepatitis patients
The only patients with alcoholic hepatitis to derive a survival benefit from extracorporeal hepatocellular therapy with C3A hepatoma cells were...
Conference Coverage
High SVR achieved in decompensated HCV patients with 12-week therapy
The findings are encouraging because current treatment options for patients with HCV who have decompensated liver disease are limited, Dr....